Literature DB >> 22441386

Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Daniel T Leung1, Mohammad Arif Rahman, M Mohasin, Sweta M Patel, Amena Aktar, Farhana Khanam, Taher Uddin, M Asrafuzzaman Riyadh, Amit Saha, Mohammad Murshid Alam, Fahima Chowdhury, Ashraful Islam Khan, Richelle Charles, Regina LaRocque, Jason B Harris, Stephen B Calderwood, Firdausi Qadri, Edward T Ryan.   

Abstract

Current oral cholera vaccines induce lower protective efficacy and shorter duration of protection against cholera than wild-type infection provides, and this difference is most pronounced in young children. Despite this, there are limited data comparing immune responses in children following wild-type disease versus vaccination, especially with regard to memory responses associated with long-term immunity. Here, we report a comparison of immune responses in young children (2 to 5 years of age; n = 20) and older children (6 to 17 years of age; n = 20) given two doses of an oral killed cholera vaccine containing recombinant cholera toxin B subunit (CtxB) 14 days apart and compare these responses to those induced in similarly aged children recovering from infection with Vibrio cholerae O1 Ogawa in Bangladesh. We found that the two vaccine groups had comparable vibriocidal and lipopolysaccharide (LPS)-specific plasma antibody responses. Vaccinees developed lower levels of IgG memory B cell (MBC) responses against CtxB but no significant MBC responses against LPS. In contrast, children recovering from natural cholera infection developed prominent LPS IgG and IgA MBC responses, as well as CtxB IgG MBC responses. Plasma LPS IgG, IgA, and IgM responses, as well as vibriocidal responses, were also significantly higher in children following disease than after vaccination. Our findings suggest that acute and memory immune responses following oral cholera vaccination in children are significantly lower than those observed following wild-type disease, especially responses targeting LPS. These findings may explain, in part, the lower efficacy of oral cholera vaccination in children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441386      PMCID: PMC3346319          DOI: 10.1128/CVI.05615-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  43 in total

1.  Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.

Authors:  D N Taylor; V Cárdenas; J Perez; R Puga; A M Svennerholm
Journal:  Am J Trop Med Hyg       Date:  1999-12       Impact factor: 2.345

2.  Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.

Authors:  D N Taylor; V Cárdenas; J L Sanchez; R E Bégué; R Gilman; C Bautista; J Perez; R Puga; A Gaillour; R Meza; P Echeverria; J Sadoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

Review 3.  Oral vaccines against cholera.

Authors:  Sunheang Shin; Sachin N Desai; Binod K Sah; John D Clemens
Journal:  Clin Infect Dis       Date:  2011-04-14       Impact factor: 9.079

4.  Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.

Authors:  Mohammad Murshid Alam; M Asrafuzzaman Riyadh; Kaniz Fatema; Mohammad Arif Rahman; Nayeema Akhtar; Tanvir Ahmed; Mohiul Islam Chowdhury; Fahima Chowdhury; Stephen B Calderwood; Jason B Harris; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

5.  Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies.

Authors:  Manohar John; Emily A Bridges; Andy O Miller; Stephen B Calderwood; Edward T Ryan
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

6.  Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.

Authors:  P J Cooper; M E Chico; G Losonsky; C Sandoval; I Espinel; R Sridhara; M Aguilar; A Guevara; R H Guderian; M M Levine; G E Griffin; T B Nutman
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

7.  Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; M Asrafuzzaman Riyadh; Sweta M Patel; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Eric J Kalivoda; Amena Aktar; M Saruar Bhuiyan; Regina C LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

8.  Natural cholera infection-derived immunity in an endemic setting.

Authors:  Mohammad Ali; Michael Emch; Jin Kyung Park; Mohammad Yunus; John Clemens
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

9.  Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Authors:  H O Hallander; M Paniagua; F Espinoza; P Askelöf; E Corrales; M Ringman; J Storsaeter
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

10.  Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

Authors:  Dipika Sur; Suman Kanungo; Binod Sah; Byomkesh Manna; Mohammad Ali; Allison M Paisley; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Seung Hyun Han; Stephen Attridge; Allan Donner; Nirmal K Ganguly; Sujit K Bhattacharya; G Balakrish Nair; John D Clemens; Anna Lena Lopez
Journal:  PLoS Negl Trop Dis       Date:  2011-10-18
View more
  34 in total

1.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

2.  Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.

Authors:  Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

Review 3.  Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors:  Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 4.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 5.  Modeling cholera outbreaks.

Authors:  Dennis L Chao; Ira M Longini; J Glenn Morris
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

6.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

7.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

Review 8.  Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.

Authors:  Shahjahan Kabir
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

9.  Spatial clustering of cholera cases in the Kathmandu Valley: implications for a ring vaccination strategy.

Authors:  Mellisa Roskosky; Mohammad Ali; Shyam Raj Upreti; David Sack
Journal:  Int Health       Date:  2021-02-24       Impact factor: 2.473

10.  Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine.

Authors:  Mohammad Murshid Alam; Daniel T Leung; Marjahan Akhtar; Mohammad Nazim; Sarmin Akter; Taher Uddin; Farhana Khanam; Deena Al Mahbuba; Shaikh Meshbahuddin Ahmad; Taufiqur Rahman Bhuiyan; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.